It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In this modern era of precision medicine, molecular signatures identified from advanced omics technologies hold great promise to better guide clinical decisions. However, current approaches are often location-specific due to the inherent differences between platforms and across multiple centres, thus limiting the transferability of molecular signatures. We present Cross-Platform Omics Prediction (CPOP), a penalised regression model that can use omics data to predict patient outcomes in a platform-independent manner and across time and experiments. CPOP improves on the traditional prediction framework of using gene-based features by selecting ratio-based features with similar estimated effect sizes. These components gave CPOP the ability to have a stable performance across datasets of similar biology, minimising the effect of technical noise often generated by omics platforms. We present a comprehensive evaluation using melanoma transcriptomics data to demonstrate its potential to be used as a critical part of a clinical screening framework for precision medicine. Additional assessment of generalisation was demonstrated with ovarian cancer and inflammatory bowel disease studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Muller, Samuel 6
; Tarr, Garth 7
; Mann, Graham J. 8 ; Yang, Jean Y. H. 9
1 The University of Sydney, Charles Perkins Centre, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, School of Mathematics and Statistics, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
2 The University of Sydney, The Westmead Institute for Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Melanoma Institute Australia, North Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
3 The University of Sydney, Charles Perkins Centre, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, School of Mathematics and Statistics, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, The Westmead Institute for Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Laboratory of Data Discovery for Health Limited (D²4H) Science Park, Hong Kong, China (GRID:grid.1013.3)
4 The University of Sydney, Melanoma Institute Australia, North Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology, Sydney, Australia (GRID:grid.413249.9) (ISNI:0000 0004 0385 0051); The University of Sydney, Faculty of Medicine and Health, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
5 The University of Sydney, Charles Perkins Centre, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Melanoma Institute Australia, North Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Faculty of Medicine and Health, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Royal Prince Alfred Hospital and NSW Health Pathology, Tissue Pathology and Diagnostic Oncology, Sydney, Australia (GRID:grid.413249.9) (ISNI:0000 0004 0385 0051)
6 The University of Sydney, School of Mathematics and Statistics, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Macquarie University, School of Mathematical and Physical Sciences, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405)
7 The University of Sydney, School of Mathematics and Statistics, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Laboratory of Data Discovery for Health Limited (D²4H) Science Park, Hong Kong, China (GRID:grid.1013.3)
8 The University of Sydney, The Westmead Institute for Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Melanoma Institute Australia, North Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Australian National University, John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
9 The University of Sydney, Charles Perkins Centre, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, School of Mathematics and Statistics, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Laboratory of Data Discovery for Health Limited (D²4H) Science Park, Hong Kong, China (GRID:grid.1013.3)




